First safety check for liver drug in patients with failing kidneys
NCT ID NCT06397872
Summary
This early-stage study tested how a drug called resmetirom, which is being developed for liver disease, is processed by the body in people with severe kidney impairment. Researchers gave the drug for 6 days to 28 participants—half with severe kidney problems and half with healthy kidneys—to compare how their bodies handled it. The main goal was to see if the drug behaves differently in people with kidney disease and to check for safety issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Madrigal Research Center
Orlando, Florida, 32809, United States
-
Madrigal Research Center
Tampa, Florida, 33603, United States
-
Madrigal Research Center
Chicago, Illinois, 60643, United States
Conditions
Explore the condition pages connected to this study.